Department of Ophthalmology, State University of Campinas, Rua Irmã Maria David, Recife, PE, Brazil.
Indian J Ophthalmol. 2012 Jul;60(4):277-81. doi: 10.4103/0301-4738.98705.
To compare the effects of preoperative use of topical anti-inflammatory prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery.
Randomized clinical trial.
This single-center, masked, randomized clinical study comprised 140 patients scheduled for cataract surgery. Patients (35 in each group) were randomized to receive placebo, prednisolone acetate, ketorolac tromethamine 0.4% or nepafenac. These eye drops were administered three times daily for the two days prior to surgery. The pupillary diameters were measured by the surgeon using a compass prior to the corneal section and at the end of surgery. The primary outcome was the number of patients with pupil ≥ 6mm at the end of the surgery; the secondary outcome was the number of patients with pupil ≥ 6mm at the beginning of the surgery.
All the patients achieved pupil ≥ 6mm at the beginning of the surgery. The number of patients in the prednisolone (29/35), nepafenac (31/35) and ketorolac (30/35) groups with pupil ≥ 6mm was greater than in the placebo group in the maintenance of intraoperative mydriasis (19/35 - P =0.003). There was no statistical difference among the prednisolone, nepafenac and ketorolac groups in the maintenance of intraoperative mydriasis (P =.791). There were no complications during surgery or related to the preoperative use of the eye drops.
Preoperative use of ketorolac, prednisolone and nepafenac was effective in maintaining intraoperative mydriasis when compared with placebo.
比较术前使用局部抗炎药醋酸泼尼松龙、酮咯酸氨丁三醇、奈帕芬那酯和安慰剂对白内障手术中维持瞳孔散大的影响。
随机临床试验。
本单中心、盲法、随机临床试验纳入了 140 名计划行白内障手术的患者。患者(每组 35 例)随机分为安慰剂组、醋酸泼尼松龙组、酮咯酸氨丁三醇 0.4%组和奈帕芬那酯组。这些眼药水在术前 2 天每日滴 3 次。手术医生使用指南针在角膜切开前和手术结束时测量瞳孔直径。主要结局为手术结束时瞳孔≥6mm 的患者人数;次要结局为手术开始时瞳孔≥6mm 的患者人数。
所有患者在手术开始时均达到了瞳孔≥6mm。在维持术中瞳孔散大方面,泼尼松龙(29/35)、奈帕芬那酯(31/35)和酮咯酸氨丁三醇(30/35)组的患者人数多于安慰剂组(19/35-P=0.003)。在维持术中瞳孔散大方面,泼尼松龙、奈帕芬那酯和酮咯酸氨丁三醇组之间无统计学差异(P=0.791)。手术过程中或与术前使用眼药水相关的均无并发症。
与安慰剂相比,术前使用酮咯酸、泼尼松龙和奈帕芬那酯可有效维持术中瞳孔散大。